Considering the roles of β-catenin and RAS in the resistance and recurrence of GC after chemotherapy, we investigated the effectiveness of a compound that destabilize both β-catenin and RAS proteins via the activation of GSK3β through the specific binding of axin, a negative regulator of the Wnt/β-catenin pathway [20], on the suppression of GC, particularly in PDX model resistant against traditional chemotherapies related with the activation of CSCs. This evidence concerns the gene AXIN1 and gastric cancer.